Saama Technologies, Inc. has announced that it has signed a definitive agreement to acquire Comprehend Systems, Inc. This agreement combines Saama and Comprehend’s respective industry positions as clinical data analytics companies. Together, Saama and Comprehend will deploy and evolve their complementary clinical analytics platforms. This agreement creates an opportunity to increase their combined market share, as well as expand their existing partner ecosystems and deliver on a mutual commitment to accelerate clinical development towards unmet patient needs.
“The Comprehend-Saama transaction creates a data analytics powerhouse with a singular vision of improving human health through the application of AI-powered solutions for actionable clinical trial insights,” said Rick Morrison, Founder and Chairman of Comprehend. "The combined 30-plus years of experience of these two companies as data analytics innovators provides exciting opportunities to speed biopharma’s development of new therapeutics and to have broader industry reach.”
“Saama and Comprehend offer life sciences companies and patient-focused organizations the ability to access and optimize a combined ecosystem of unique, state-of-the-art analytics solutions and visualization tools that enable the re-imagination of clinical development and the realization of precision medicine,” said Rebecca Daniels Kush, Ph.D., founder of the Clinical Data Interchange Standards Consortium (CDISC), and member of Saama’s Clinical Board of Advisors.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.